Objective The immunosuppressive drug tacrolimus requires strict therapeutic monitoring due
to its narrow therapeutic index and great inter-individual variability. Cytochrome P450 3A4 …

Objective: Tacrolimus is an immunosuppressive drug with a narrow therapeutic range and
wide interindividual variation in its pharmacokinetics. Cytochrome P450 (CYP) 3A and P …

Background. A body-weight-based dose of tacrolimus often results in marked individual
diversity of blood drug concentration. Tacrolimus is a substrate for cytochrome P450 (CYP) …

Abstract Background Cytochrome P450 (CYP) 3A4 and 3A5 are major isoforms involved in
the metabolism of tacrolimus, with the CYP3A5 gene being more polymorphic. It is …

OBJECTIVE: The objective of this study was to assess the influence of CYP3A5 and MDR1
genetic polymorphisms on tacrolimus pharmacokinetics in Japanese renal transplant …

The impact of CYP3A and MDR1 gene single‐nucleotide polymorphisms on long‐term
tacrolimus disposition and drug‐related toxicity has not been assessed. A study was …

Aim: Tacrolimus is a substrate of CYP3A4 and CYP3A5. The present study investigated the
impact of the CYP3A4* 1/* 1G polymorphism compared with CYP3A5 genotypes on the …

Background. Tacrolimus pharmacokinetic characteristics vary greatly among individuals.
Tacrolimus is a substrate of cytochrome P450 (CYP), of subfamily CYP3A. CYP3A activity is …

BACKGROUND: Genetic polymorphisms of metabolism enzymes or intestinal drug
transporters may affect pharmacokinetic responses to immunosuppressive drugs in renal …

The aims of this study were to investigate the influence of CYP3A5 and MDR1 genetic
polymorphisms on tacrolimus pharmacokinetics in Chinese renal transplant recipients, so as …